Economic Evaluation of Lecanemab for Early Symptomatic Alzheimer's Disease in South Korea
Lecanemab's high cost poses a challenge to its inclusion in the National Health Insurance formulary under South Korea's current WTP thresholds. Strategic price adjustments and patient targeting are essential to enhance its economic viability. These findings provide valuable insights for policymakers and stakeholders in balancing treatment outcomes and resource allocation for AD management.
Authors
- Song Hee Hong (ORCID: https://orcid.org/0000-0002-5188-9837)
- Maryanne Kim (ORCID: https://orcid.org/0000-0002-4618-4760)
- Seungyeon Shin (ORCID: https://orcid.org/0009-0006-7273-9447)
Institutions
- Seoul National University (KR)
- University of California, San Francisco (US)
- National University College (PR)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-07-20
- DOI
- https://doi.org/10.1007/s41669-025-00593-z
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 6.26
Funders
- Seoul National University